Interesting to note that on page 15,
Avacta Diagnostic “ Review and Growth “, beneath the Growth title, there is now a mention of
“ potential future spin-out opportunity “!
Would indicate a separate US listing of the therapeutic division, with a pipeline of selective and focused out-licensing.
Interesting article on CDMO and I thought relevant to Affyxell and GenScript Pro Bio.
From article:
“As the CGT industry matures, CDMO outsourcing is expected to increase dramatically, playing an even more critical role in advanced therapy production. In addition, the IP landscape and quality control standards will become clearer as regulations are better defined, resulting in an even higher degree of expertise and level of capabilities offered in the outsourcing service provider marketplace. “
https://www.biopharmadive.com/spons/cell-and-gene-therapy-is-coming-of-age/688569/
It is a matter of, can one afford to hold on and buy more on weak days and take profits on the right days.
Profit taking because you want to and not because you have to.
Right now you have the easiest 50% you can make in the market, with an avalanche of RNS’ around the corner.
Note one does not have to be rude to make your point!
This time just printing 10/ buys till the market steps back and you have 10-20 and testing the buyer.
He will then test the market and start buying in 100/ and see what is left.
A couple of size buy orders and you have 30/ offered.
Once lifted and you know it is not stopping here and then RNS.
New price range coming up
Https://www.biospace.com/article/regenerative-medicine-challenges-hinder-their-development-and-use-gao/
+
The watchdog group also recommended that federal agencies could help by supporting public-private partnerships that can share costs for manufacturing facilities.
Lots of Corporate news in the sector:Roviant Sciences(ROIV) in discussions to sell its experimental drug RVT-3101 for treating Bowel diseases to Roche, could be worth over $7bill.
Eli Lilly to aquire Versanis, $2bill.
Caribou stock offering $125mill
Frequency Therapeutics merger with Korro Bio
Sagimet(SGMT) priced its upsized IPO at $16.00
and then with Avacta we could have a RNS on Monday with Cohort update and throw in a License agreement as well.
and more to come.
New York offices ? perhaps close to Wall street
US buyers are laughing as they are picking up stock 30% below next week’s level and off course RNS on Cohort etc
Fundraise is wishful thinking from the usual gang, meanwhile back in the real world, offer price being lifted again and again.
I do like Friday’s, plenty of upside. Let us see closing price!
Following the acquisitions in the Diagnostic division and closing the Cambridge office, interesting to note the comment on page 45 in Avacta’s business review, ref. the diagnostic division “ benefiting from synergies across the division”!
Believed to be the first FDA IND clearance of an allogeneic dual CAR-T therapy targeting CD19 and CD20
SAN DIEGO, July 5, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for P-CD19CD20-ALLO1, the Company's first allogeneic dual CAR-T cell product candidate, which targets both CD19 and CD20 antigens for the treatment of relapsed or refractory B-cell malignancies and is being developed in partnership with Roche.
More funds to Novartis:
June 30 (Reuters) - Bausch + Lomb Corp (BLCO.TO) will purchase a dry-eye drug from Swiss pharma company Novartis (NOVN.S) for $1.75 billion, the Wall Street Journal reported on Friday, as the contact lens maker seeks to capitalise on a growing market for the disease's treatment.